BioCryst Pharmaceuticals | BCRX - Operating Profit


BioCryst Pharmaceuticals reported $-2.54M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
BioCryst Pharmaceuticals USD -2.54M 10.23M Dec/2024
Chugai Pharma JPY 169.01B 12.52B Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novavax USD -134.02M 296.12M Sep/2024
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025